Aug 22, 2011, 07.39 PM IST
Biotech firm Biocon today said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms.
This partnership establishes a cost-efficient global footprint for clinical pharmacology services, providing an opportunity for both organisations to engage pharmaceutical clients strategically, Biocon said in a statement.
Clinigene Chief Operating Officer Abhijit Barve said: "Pharmaceutical clients globally are increasingly seeking strategies to expedite their early clinical development, streamlining processes while maintaining high quality.
"Our strategic partnership is designed to deliver this in a very cost-effective manner."
The company, however, did not disclose financial details.
"With Clinigene's expertise and cost-effective approach... Our clients are able to easily structure a program for their compound that delivers high-value value," Spaulding Clinical CEO Randol Spaulding said.
Shares of Biocon today closed at Rs 329.20 on the Bombay Stock Exchange, up 2.01% from its previous close.
Biocon stock price
On December 12, 2013, Biocon closed at Rs 391.35, down Rs 4.8, or 1.21 percent. The 52-week high of the share was Rs 408.80 and the 52-week low was Rs 255.00.
The company's trailing 12-month (TTM) EPS was at Rs 15.02 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 26.06. The latest book value of the company is Rs 110.34 per share. At current value, the price-to-book value of the company is 3.55.
Action in Biocon
Video of the day
Dec 11 2013, 09:54
- in Business
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.